Last €1.02 EUR
Change Today -0.038 / -3.58%
Volume 0.0
VPA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:09 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (VPA) Snapshot

Open
€1.02
Previous Close
€1.06
Day High
€1.02
Day Low
€1.02
52 Week High
09/6/13 - €1.66
52 Week Low
06/6/14 - €0.73
Market Cap
53.5M
Average Volume 10 Days
1.0K
EPS TTM
--
Shares Outstanding
52.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEO PHARMACEUTICALS INC (VPA)

aveo pharmaceuticals inc (VPA) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (VPA) Details

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Founded in 2001

aveo pharmaceuticals inc (VPA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $567.9K
Chief Scientific Officer
Total Annual Compensation: $334.5K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (VPA) Key Developments

AVEO Oncology Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

AVEO Oncology reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $17,959,000 or $0.35 per basic and diluted share against net loss of $31,913,000 or $0.62 per basic and diluted share a year ago. Collaboration revenue was $1,846,000 and loss from operations was $17,465,000 against collaboration revenue was $324,000 and loss from operations was $31,072,000 a year ago. The company had net cash outflows of approximately $23,000,000 compared to $30,000,000 in first quarter of 2014. The company's construction related capital expenditures were $4,000,000, down from $7,800,000 in first quarter of 2014. These construction-related capital expenditures are associated with AVEO's corporate headquarters at 650 E. Kendall St., Cambridge, MA. For the six months, the company reported net loss of $24,409,000 or $0.47 per basic and diluted share against net loss of $65,998,000 or $1.31 per basic and diluted share a year ago. Collaboration revenue was $17,135,000 and loss from operations was $23,357,000 against collaboration revenue was $647,000 and loss from operations was $64,227,000 a year ago.

AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 2000 Index

AVEO Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 3000 Index

AVEO Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPA:GR €1.02 EUR -0.038

VPA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VPA.
View Industry Companies
 

Industry Analysis

VPA

Industry Average

Valuation VPA Industry Range
No financial data is available for VPA.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit www.aveopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.